Introduction
For decades, morphology and histochemical staining have been the gold standards for definition of AML according to the FAB (French-American-British Cooperative Group) classification. 1 Immunophenotyping and molecular genetics brought new insights with considerable therapeutic implications into the biology of these diseases. Besides standard chemotherapy hematopoietic stem cell transplantation is an important treatment option for AML. If HLA matched related or unrelated donors are not available, autologous transplantation has to be considered as an additional treatment choice. Therefore, distinction between healthy and malignant stem cells has become a major focus of interest and various purging techniques have been proposed in order to improve remission rates and duration.
Current concept of hematopoietic stem cell development
It is a well established model that blood cells derive from pluripotent progenitor cells with the capacity for self-renewal and differentiation. More differentiated cells are generally considered to be more committed to a certain lineage with concomitant loss of self-renewal capacity. Although cell morphology provides good information about the developmental stages of bone marrow cells, immunophenotyping of blood cells is of great help in identifying lineage determination especially in early progenitor cell compartments. Differentiated cells display distinct patterns of antigen expression, like CD11b, CD13, CD33, CD14, CD15 and CD66 antigens on myelomonocytic cells. These lineage markers (lin + ) are not expressed on early hematopoietic cells. Cells of intermediate differentiation level, which are still capable of giving rise to differentiated progeny, co-express the progenitor cell antigen CD34 and lineage markers. These cells are capable of colony formation in short-term assays termed clonogenic assays such as colony-forming units (CFUs) or burst-forming units (BFUs). In the case of myeloid differentiation they typically carry the CD33 and CD13 antigen.
The leading concept has been that stem cells harbor the CD34 antigen. This led to widespread use of CD34-enriched cell populations in human transplantation. To distinguish the small amount of real stem cells with self-renewal capacity from the majority of CD34-positive cells that have already acquired some degree of differentiation is still the focus of intense interest since the discovery of the CD34 antigen. 2 Different model systems are applied to define stem cells with pluripotent hematopoietic potential. Many groups use irradiated non-obese diabetic mice with severe combined immunodeficiency syndrome (NOD/SCID mice) as recipients for human candidate progenitor cells. Others apply in vitro cell culture systems to identify the cells of interest such as long-term culture-initiating cells (LTC-ICs) and limiting dilution assays. The sheep in utero transplantation system seems to be most reliable, because the human progenitor cells are transferred into the sheep fetus in utero before the development of the ovine immune system. 3, 4 There is still controversy about suitability and comparability of these model systems for the definition of pluripotent stem cells. 5 Largely through application of in vitro assays, the surface antigen expression pattern of human hematopoietic stem cells has been defined as CD34 + CD38
− . Several other antigens have been described to accompany CD34 expression. Their presence or absence has been reported to define different stem cell populations. The CD45 antigen is expressed on primitive hematopoietic stem cells as well as on all nucleated peripheral blood cells. If the CD34 cells carry the CD90 antigen (Thy-1), they are thought to represent early progenitor cells with superior proliferation and differentiation potential compared to CD90 − cells. 6, 7 The same is the case for the AC133 antigen 8 and the data suggest that the CD82 antigen may also be expressed on stem cells. 9 Recently, the KDR receptor also known as vascular endothelial growth factor receptor 2 (VEGFR2) has been reported to be a new marker that distinguishes pluripotent hematopoietic stem cells from lineage-committed stem cells. 10 In contrast to this finding, other groups report that VEGFR may define a subtype of hematopoietic progenitor cells with endothelial features. 11 The signalregulatory proteins (SIRPs) have been described very recently as candidate stem cell proteins that are co-expressed on bone marrow CD34 + , AC133
+ and CD90 + cells. 12 Expression of CD117 antigen (c-kit), 13 a receptor tyrosine kinase, is low on early human CD34 cells and subsequently becomes more detectable as the maturation process continues. 14 This pattern of antigen expression is also true for HLA-DR 15 and CD38, 16 Flt-3 receptor and interleukin-6 (IL-6) receptor signal transducing element (gp 130), 17 as well as CD71, the transferrin receptor. 18 It varies with the source of progenitor cells. 16 The dogma of the CD34-positive multipotent stem cell has been questioned for about 3 to 4 years. Several groups reported that the earliest hematopoietic progenitor cell has a CD34 − lin − phenotype [19] [20] [21] characterized by the CD45 antigen and lack of expression of c-kit, Thy-1 and lineage markers. Expression of CD38 seems to be variable. 22 At first sight these findings appear to be in contrast to the established model of CD34 + CD38 − phenotype of pluripotent progenitor cells. Other recent publications confirmed the idea of CD34-negative earliest stem cells and present intriguing new data about progenitor cell development, demonstrating the reversibility of CD34 expression on pluripotent hematopoietic cells. This was confirmed in the murine system 23 as well as in humans. 24 A new model was consequently proposed: CD34 expression may represent a reversible activation state of hematopoietic stem cells, as revised by Goodell.
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During the past year some groups reported that adult human stem cells have the ability to reconstitute human bone marrow even across the tissue border. They showed that stem cells from the adult brain retained the youthful ability to become several different kinds of tissues. It has been demonstrated that gene-marked adult neural stem cells were able to engraft the bone marrow of sublethally irradiated mice and may thus function as hematopoietic progenitor cells capable of differentiating into myeloid and lymphoid progeny. 26 Additionally, non-hematopoietic cells isolated from murine adult skeletal muscle seemed to exhibit even more bone marrow reconstituting hematopoietic activity as compared to whole bone marrow. 27 These data evoked controversy of the view that the developmental potential of stem cells is restricted to the differentiated elements of the tissue in which they reside. Figure 1 summarizes these data and hypotheses about normal stem cell phenotype and maturation.
Characterization of the malignant cell clone in acute myeloid leukemia
Acute myeloid leukemia (AML) is thought to be a clonal disorder of poorly differentiated hematopoietic progenitor cells. The current concept of malignancy is based on the idea that altered gene function either confers a growth advantage to a cell or prevents apoptosis. Activation of oncogenes or loss of function of tumor suppressor genes, disturbance of DNA repair genes, alteration of cell cycle genes, etc, results in factor-independent uncontrolled growth and lack of contact inhibition. The idea of a clonal evolution process of malignancy is an important part of that concept, meaning that no single event transforms a cell but additional genetic alterations accumulate and synergize in growth promotion or apotosis inhibition. 28 This concept is called 'multistep-carcinogenesis'. Many different kinds of mutations are known to result in altered gene function, eg point mutations, deletions or inversions. These aberrations are often observed in solid tumors. In leukemia and lymphomas, however, gross chromosomal alterations like balanced translocations occur quite frequently, resulting in fusion of unrelated genes and subsequently yielding chimeric proteins with altered functions.
At least 60% of de novo AML harbor cytogenetic abnormalities. 29 High-resolution banding techniques suggest that almost all patients have cytogenetic abnormalities. 30 Translocations between chromosome 8 and 21, between 15 and 17 and inversions of chromosome 16 have been described most commonly in AML. Quite often AML patients harbor a leukemic clone with multiple cytogenetic aberrations.
During the past years, there has been extensive research on the molecular background of these chromosomal aberrations which elucidated the understanding of leukemogenesis. The t(8;21), which characteristically occurs in FAB M2, results in the AML1-ETO fusion protein. AML1 is the ␣-subunit of core binding factor (CBF) that heterodimerizes with the ␤-subunit and functions as a transcription factor which plays a key role in hematopoiesis. The chimeric protein retains the ability to heterodimerize and bind DNA, but potentially inhibits transcription. 31, 32 It also acts as a transactivator for other genes 33 and has been shown to inhibit terminal granulocytic differentiation in cell lines. 34 In inversion 16 or less common t(16;16) the ␤-subunit of CBF is altered due to fusion with the tail domain of a smooth muscle myosin heavy chain (SMMYHC), resulting in multimerized complexes of CBF␣ and CBF␤ subunits. These complexes are sequestered preferentially therefore interfering with DNA binding of CBF and its transactivation function. 35 Inversion of chromosome 16 is associated with AML FAB subtype M4eo.
The FAB M3 leukemia has a unique translocation pattern, the t(15;17), which results in fusion of the retinoic acid receptor (RAR␣) to the promyelocytic leukemia gene (PML). DNA binding of this alterated receptor is inappropriate causing a differentiation blockage in myeloid cells.
However, for other less common translocations occurring in AML such as t(3;21), t(12;21), t(9;22), etc, loss or gain of function from genes involved in those lesions have also been described intensively. [35] [36] [37] [38] [39] Excellent reviews on the genes involved in AML with those common translocations providing extensive information about the molecular details and the consecutive biologic effects are presented by Appelbaum et al 40 and Friedman. 35 In addition, there are many reports about gene alterations in AML without any defined gross chromosomal abnormality such as ras-oncogene mutations, [41] [42] [43] 42, 56 Differentiation between healthy and malignant progenitor cells in acute myeloid leukemia Although extensive research has provided a better understanding of how chromosomal aberrations can disturb gene function resulting in growth advantage or block of differentiation, it is still difficult to distinguish normal from leukemic stem cells. Normal human stem cells and malignant leukemic blast cells exhibit similar morphological, biological and phenotypic features. It is not always possible to distinguish malignant blasts from healthy progenitors solely by morphology. About 20% to 50% of the acute myeloid leukemias show aberrant antigens, 57 but almost all aberrant antigen combinations can
Figure 1
Summarization of recent hypotheses of human stem cell development. Model of CD34 expression in the human bone marrow during maturation progress. The earliest stem cell is probably not tissue-determined, quiescent and with self-renewing capacity. Possibly through cell matrix interaction it can acquire a tissue specific phenotype and function. This early hematopoietic progenitor cell with ability for selfrenewal seems to be CD34 − CD45 + exhibiting variable expression of CD38. On activation this cell can acquire a CD34 + phenotype and give rise to differentiated progeny. It displays a strong CD34 expression which is reversible if an activation equilibrium occurs. The activated CD34 + cell is partially capable of self-renewal and long-term engraftment, especially if it has a certain pattern of co-expressed antigens indicating an immature developmental stage like CD90 + , DR − . As maturation proceeds the co-antigen expression pattern changes and the clonogenic potential improves while self-renewal capacity persists. It should be emphasized that maturation in reality is a continuing process unlike this diagram, which suggests a stepwise maturation with defined stages. Antigen expression is probably a gradually increasing or decreasing process reflecting the fluent maturation progress. also be detected in a small percentage of healthy individuals. Aberrant antigen expression may also vary during the course of AML treatment and is therefore not suitable as a single reliable marker of the malignant cell clone.
In the absence of aberrant antigen combinations, malignant myeloid cells in AML often display a very similar surface protein expression pattern as compared with their healthy CD34 counterpart. Until now there has been almost no antigen described that has proved to be expressed on malignant blast cells exclusively. The AC133 antigen is neither specific for non-AML blast cells nor for myeloid blast cells. 58, 59 The CD82 antigen is also expressed on hematopoietic progenitor cells and on AML cells. 9 The Flt3-receptor tyrosine kinase, which is up-regulated on normal activated stem cells, has high m-RNA and protein expression levels in AML cells. 60 However, the internal tandem duplication within the juxtamembrane region of that receptor occurs exclusively in AML cells. It has been reported that the expression pattern of adhesion molecules is different in cells from AML patients and normal stem cells, but the differences are quantitative and not absolutely specific. 61 Whether the KDR receptor also occurs on myeloid leukemia cells has not been investigated until now. The Leukemia human signal-regulatory protein (SIRP), described as a stem cell marker very recently, is a serious candidate protein for distinction between hematopoietic progenitor cells and myeloid blasts because the latter cells do not express that protein or express it in a significantly reduced manner. 12 Although the malignant leukemic blasts in AML generally arise from very early CD34 + progenitor cells, the FAB subtypes of acute myeloid leukemia seem to have different differentiation levels. The CD13 and CD33 antigens and myeloperoxidase that characterize normal myeloid progenitor cells are abundantly expressed on almost all AML cells, but are variable in FAB M0, which is considered to be a rather undifferentiated leukemia. Most of the leukemic cells of this FAB subtype exhibit a CD34 + CD38 − antigen expression and lack other progenitor cell antigens. 62 The c-kit antigen expression is present in about 60% of AML in general but differs between FAB subtypes and karyotype, AML M0 and M1 leukemias show more pronounced c-kit-antigen expression as compared with M5 leukemias. 63 The M2 leukemia which frequently harbors the t (8;21) 70 meaning that in this disease leukemic cells resemble the earliest CD34 cell progenitor phenotype. The patients examined in this study had progressive disease with poor response to chemotherapy treatment. The discordant findings could be explained with the different study populations (primary vs secondary AML, different FAB subtypes). It is also very likely that the malignant cell clone predominates the earliest stem cell compartments only in later or progressive stages as is the case in chronic myeloid leukemia. 71 However, this controversy reflects the difficulty of defining early and more mature acute myeloid leukemia cases solely by immunophenotype. Acute myeloid leukemias that predominantly display a CD34 − CD33 + phenotype might also harbor early malignant clones within the CD34 + CD90 + population. This clone will probably expand during disease progression due to loss of the ability to differentiate further or some growth advantage after chemotherapy treatment. In CML it has been demonstrated that the early malignant bcr-abl-positive CD34 + cells stimulate their growth through autocrine IL-3 and G-CSF release. These cells lose this capacity during maturation and differentiation. 72 A similar mechanism could be assumed for AML cells.
The discordance of our findings as compared with the literature can also be explained in part by different methods applied while addressing the question of developmental stages of stem cells. Most investigators make use of karyotypic abnormalities in AML cells in order to identify the malignant clone applying either conventional G-banding cytogenetic analysis, interphase fluorescence in situ hybridization (FISH) analysis or PCR-based molecular genetic techniques. Several pitfalls have been demonstrated for these techniques. In certain cytogenetic lesions such as monosomy 7 or t(15;17) standard G-banding analysis obscures the high number of aberrant karyotypes within blood cell fractions, probably due to different proliferative abilities of the malignant clone in vitro. 73, 74 One could assume that with other leukemic karyotypic lesions false positive results could be obtained with the standard cytogenetic analysis because of higher proliferative potential of the malignant cell type in cell culture compared to healthy blood cells. In some specific lesions, interphase FISH seems to be superior in detecting the cytogenetic aberration. Although FISH is a widely accepted sensitive standard technique for the detection of specific cytogenetic aberrations in semi-quantitative manner, false positive signals can appear due to artifacts when analyzing three-dimensional cells from a two-dimensional perspective. Therefore, cut-off levels have to be defined for each probe on healthy individuals. If the cell of interest has been exposed to stressful events such as sorting, culturing etc, cut-off levels may be significantly higher and may vary considerably due to a higher amount of dead cells within a fraction or squeezed nuclei resulting in interpretation failure. 75 To avoid these difficulties, polymerase chain reaction (PCR) analysis can be applied as an equal or even superior technique. It is a well established method for sensitive detection of specific gene rearrangements such as bcr-abl, t(15;17) or t (8;21) . For detection of inversion 16 it seems to be more reliable than standard cytogenetic analysis. 76 Despite the high sensitivity, standard PCR analysis is not suitable for exact quantification. New technologies for REAL-time PCR analysis may partially overcome that problem. However, only defined genetic alterations can be sensitively detected by PCR and FISH technique and require well defined probes that are available only for the most common genetic lesions. Since AML patients display a variety of chromosomal defects, which are often not detectable either with FISH or PCR analysis, combination of both techniques with standard cytogenetic analysis is recommended.
Different genetic alterations within leukemic cells seem to have very unique biological features reflecting the heterogeneity of AML cases. All patients whose blasts harbor t(8;21) and inv16 (CBF + leukemias) have a favorable outcome. 77, 78 One could speculate that in those leukemias the cells are more susceptible to chemotherapy but there is no proven explanation for the benefit of those rearrangements. Promyelocytes in t(15;17) M3 leukemia respond to retinoic acid treatment with differentiation. This treatment improves survival in AML patients with this particular lesion. Another type of acute myeloid leukemia, familial AML with monosomy 7, has been shown to affect very early multipotent progenitor cells and to have extraordinarily poor patient survival. 79 In addition, AML patients with a history of myelodysplastic syndrome and monosomy 7 often have a fatal outcome. One could assume that chromosome 7 harbors a gene important in apoptotic pathways but until now such a target gene has not been identified. Another example of biological significance of certain genetic lesions is the Flt3 gene. Its alteration can modify the proliferative ability of leukemic cells. 47 As mentioned above, biological features of leukemic and normal cells in AML are often similar. 69 Leukemic cells can form short-term colonies and have long-term proliferative potential in vitro. 15 Similar to normal CD34 + progenitors some AML cells can be forced to differentiate into dendritic cells 80 and can also be stimulated to differentiate according to their lineage, for example with CD44 antibody in M1/2 to M5 leukemia. 81 To date, it can be stated that combined analyses of stem cell phenotypic antigen expression, genetic lesions and biological features in AML provide useful tools to detect differences between normal and malignant progenitor cells that are of clinical benefit possibly providing data for new sorting strategies in this disease.
Perspectives
It has been reported that in chronic myeloid leukemias (CML) or myelodysplastic syndrome (MDS) sorting of benign stem cells with a certain phenotype could be accomplished. 71, 82 These diseases are also considered to be clonal disorders of multipotent progenitor cells. 83 But to date for autologous transplantation, no reliable purging method exists for obtaining leukemia free grafts.
The current model system of CD34 − phenotype of the earliest progenitor cell and switch of the resting stem cell from CD34 − to CD34 + phenotype due to external activation stimuli gives rise to the question whether this cell might be free from leukemic genetic lesions providing a source for healthy stem cells in autologous transplantation. This hypothesis seems likely, because the very early progenitor cell is probably a dormant cell, less prone to gene altering events that can occur in proliferating cells. If chemotherapy agents or radiation alter the recovery state of the bone marrow, the stem cells attain an activation state upon external proliferation stimuli. One could imagine that through activation the prior dormant stem cells respond with multiple surface receptor up-regulation and therefore become CD34 + cells. If some of these activated CD34
+ cells enter the cell cycle in order to reconstitute the bone marrow cell pool they become susceptible targets for DNA damaging agents such as benzene or alkylating substances. These cells are more prone to becoming leukemic than dormant cells. The effort of detecting a leukemic-free cell compartment within the CD34 + population might therefore be frustrating.
In addition to their dormant state, CD34 − hematopoietic stem cells possibly have potent mechanisms protecting them from genetic damage like efflux pumps for toxic agents. Therefore, the dye efflux definition of CD34 − stem cells seems likely. 22 The expectation that these cells might display a compartment free of leukemic cell clones is very promising but needs to be proven in future studies. If these early progenitors could be identified and mobilized in vivo for collection, only very few cells might be sufficient for engraftment in stem cell transplantation settings and might provide a new source of leukemic-free graft with reduced risk of leukemic relapse. According to that model, CD34
− cells will turn into CD34 + cells that up-regulate growth factor receptors, kit-ligand and other surface antigens in response to external stimuli, resulting in augmented self-renewal and differentiation potential. This new perspective for autologous bone marrow transplantation without risk of malignant cell contamination becomes even more likely if one considers the data about bone marrow repopulating potential of non-hematologic stem cells from brain or muscle tissue. It is not expected that these tissues will be affected by the malignant leukemic cell clone thus possibly providing a safe source for leukemic-free bone marrow reconstituting cells useful for stem cell transplantation. We assume that these exciting new data will challenge scientists and physicians to co-operate in further investigations in the area of stem cell characterization.
